Somatropin
Investigación publicada y base de evidencia
Somatropin is a 191-amino-acid recombinant form of human growth hormone that acts through the growth hormone receptor and the downstream JAK/STAT pathway, largely via hepatic and local induction of insulin-like growth factor 1 (IGF-1). It has been an approved therapeutic since the mid-1980s and carries one of the larger clinical evidence bases in endocrinology, spanning childhood and adult growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age short stature and idiopathic short stature. The contemporary literature is dominated by systematic reviews, network meta-analyses and consensus statements, with a recent centre of gravity on long-acting weekly analogues (somapacitan, somatrogon, lonapegsomatropin, pegylated formulations) benchmarked against daily somatropin. Long-term registry and cohort surveillance has focused on mortality, malignancy incidence and metabolic outcomes.
- La somatropina es una forma recombinante de la hormona del crecimiento humana aprobada desde los años 1980.
- Estudios en niños y adultos reportan mejoras en el crecimiento y resultados metabólicos.
- Los datos a largo plazo sobre formulaciones semanales y riesgo de cáncer siguen siendo limitados.
42 estudios · 13 desde 2023 · más reciente 2026
- Estudios citados
- 42
- Publicados en 2023+
- 13
- Artículo más reciente
- 2026
- Última revisión
- oct 2026
Temas recurrentes en la literatura
- growth hormone deficiency
- IGF-1
- GH/IGF-1 axis
- long-acting growth hormone analogues
- height velocity and adult height
- Turner syndrome
- Prader-Willi syndrome
- small for gestational age
- transition care
- body composition
- treatment adherence
- long-term safety surveillance
42 estudios publicados.
Ordenados por solidez del diseño del estudio, luego por antigüedad. Cada entrada enlaza a su registro fuente para que el hallazgo pueda verificarse contra el artículo en lugar de tomarse bajo nuestra palabra.
- 01Guía clínica2025
Long-Acting Growth Hormone Therapy in Pediatric Growth Hormone Deficiency: A Consensus Statement
Maniatis A, et al. · The Journal of Clinical Endocrinology and Metabolism · international consensus statement, panel of 11 paediatric endocrinology experts from 10 countries
The panel recorded that weekly long-acting formulations reduce injection frequency and treatment burden relative to daily somatropin and may support adherence, while noting that long-term and real-world outcome data remain lacking.
- 02Guía clínica2025
Consensus and controversies about diagnosing GH deficiency: a Delphi survey by the GH research society
Arlien-Søborg MC, et al. · Pituitary · Delphi survey, 43 panellists (18 paediatric, 25 adult endocrinologists) from 14 countries
Agreement on diagnostic criteria for growth hormone deficiency was substantially higher among adult endocrinologists (88%) than paediatric endocrinologists (59%), with the principal areas of disagreement concerning the choice and interpretation of stimulation tests.
- 03Guía clínica2023
International Consensus Guideline on Small for Gestational Age: Etiology and Management From Infancy to Early Adulthood
Hokken-Koelega ACS, et al. · Endocrine Reviews · international consensus guideline informed by systematic review of approximately 1,300 articles, experts from 10 paediatric endocrine societies
The guideline set out management of short stature persisting after birth small for gestational age, including timing of growth hormone initiation in early childhood and the option of adjunctive GnRH analogue therapy in selected cases to optimise adult height.
- 04Guía clínica2022
Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement
Boguszewski MCS, et al. · European Journal of Endocrinology · international consensus statement, 55 participants representing 10 professional societies
The panel concluded that the evidence reviewed did not support an association between growth hormone replacement and primary tumour recurrence or cancer recurrence in survivors, while recommending continued surveillance.
- 05Guía clínica2019
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE.
Yuen KCJ, et al. · Endocr Pract · AACE/ACE clinical practice guideline, 58 graded recommendations
The guideline issued 58 recommendations on diagnosis and treatment of adult and transition-age GHD, emphasising appropriate stimulation-test cut-points and caution with GH and IGF-1 assays, and discussed unapproved uses, long-term safety and long-acting preparations.
- 06Guía clínica2016
Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency.
Grimberg A, et al. · Horm Res Paediatr · Pediatric Endocrine Society GRADE-based guideline
The guideline gave GRADE-based recommendations for GH treatment in children with GHD, idiopathic short stature and primary IGF-I deficiency, added recombinant IGF-I therapy for the first time, and identified areas needing further research.
- 07Revisión sistemática2026
Long-Acting Growth Hormone Versus Daily Growth Hormone for Growth Hormone Deficiency Patients: A Network Meta-Analysis of Clinical Trials
Abadi A, et al. · Endocrinology, Diabetes & Metabolism · network meta-analysis of 18 randomised controlled trials, n=3,137 patients with growth hormone deficiency
Once-weekly long-acting formulations were broadly comparable to daily somatropin for linear growth outcomes, with weekly PEGylated rhGH ranking highest for height velocity in the network and no signal of compromised safety across comparators.
- 08Revisión sistemática2026
Comparison of efficacy and safety between long-acting growth hormone and short-acting growth hormone in isolated growth hormone deficiency: a systematic review and meta-analysis of 16 randomized controlled trials involving 2,435 pediatric patients
Shen ZZ, et al. · Frontiers in Pediatrics · systematic review and meta-analysis of 16 randomised controlled trials, n=2,435 paediatric patients with isolated growth hormone deficiency
Long-acting preparations showed a small advantage in first-year height gain over daily somatropin, the effect being concentrated in the PEGylated subgroup, while adverse event rates were comparable between the two treatment schedules.
- 09Revisión sistemática2026
Long-acting growth hormone for treating growth hormone deficiency in children: a meta-analysis of randomized controlled trials focusing on changes in body mass index
Levaillant L, et al. · The Journal of Clinical Endocrinology and Metabolism · meta-analysis of randomised controlled trials with extension phases, n=585 children (346 long-acting, 239 daily)
BMI standard deviation score rose significantly over the first 12 months in children receiving long-acting growth hormone, whereas no comparable change was observed with daily somatropin, identifying a metabolic difference between the two dosing schedules.
- 10Revisión sistemática2026
Safety and efficacy of somapacitan in adults with growth hormone deficiency who were switched from daily growth hormone therapy: A systematic review and meta-analysis
Kamrul-Hasan ABM, et al. · Growth Hormone & IGF Research · systematic review of 5 studies with meta-analysis of 4 randomised controlled trials, n=297 adults switched from daily rhGH
Switching adults from daily somatropin to once-weekly somapacitan maintained comparable efficacy and safety, with modest differences reported in glucose homeostasis measures and no excess of serious adverse events.
- 11Revisión sistemática2026
GH-IGF-1 axis and rhGH outcomes in children with GHD, ISS and SGA: a systematic review and meta-analysis
Soliman AT, et al. · Journal of Pediatric Endocrinology & Metabolism · systematic review and meta-analysis of 47 studies (2005-2024), n=18,642 children (9,214 GHD, 6,807 ISS, 2,621 SGA)
First-year height velocity response to rhGH was greatest in complete growth hormone deficiency, exceeding idiopathic short stature by approximately 0.80 cm/year and small-for-gestational-age short stature by approximately 0.62 cm/year, indicating diagnosis-dependent responsiveness of the GH/IGF-1 axis.
- 12Revisión sistemática2025
Long-term growth hormone effects in Prader-Willi syndrome: A systematic review and meta-analysis
Almutadares MN, et al. · Saudi Medical Journal · systematic review of 41 studies with 30 pooled in meta-analysis, patients with Prader-Willi syndrome
Growth hormone treatment was associated with increases in height standard deviation score of approximately 1.05 to 1.53 depending on treatment duration, reductions in BMI standard deviation score and elevated IGF-1, with the authors emphasising the need for metabolic monitoring.
- 13Revisión sistemática2024
Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-analysis
de Fries Jensen L, et al. · Advances in Therapy · systematic literature review with Bayesian network meta-analysis, 6 trials (2 somapacitan, 3 somatrogon, 1 lonapegsomatropin)
No statistically significant differences in 52-week growth outcomes were detected between somapacitan, somatrogon and lonapegsomatropin, and all three were comparable to daily somatropin in efficacy and tolerability.
- 14Revisión sistemática2024
Growth Hormone Treatment to Final Height in Turner Syndrome: Systematic Review
Aversa T, et al. · Clinical Therapeutics · systematic review of 9 studies published 2010-2021 in Turner syndrome
Growth hormone treatment at adequate dose was associated with attainment of adult heights within the target range, with the largest height gains accrued during the prepubertal period; karyotype did not predict treatment response.
- 15Revisión sistemática2023
Meta-analysis of mortality in adults with growth hormone deficiency: Does growth hormone replacement therapy really improve mortality rates?
van Bunderen CC, Olsson DS · Best Practice & Research. Clinical Endocrinology & Metabolism · meta-analysis of observational cohort studies of adults with growth hormone deficiency
Although mortality in hypopituitary cohorts appeared closer to background rates in the growth hormone replacement era, the authors concluded that selection bias and time bias precluded high-quality evidence that replacement itself improves mortality.
- 16Revisión sistemática2008
Systematic review: the effects of growth hormone on athletic performance.
Liu H, et al. · Ann Intern Med · systematic review of 27 RCT samples, n=303 GH recipients, healthy young adults
GH increased lean body mass by 2.1 kg but did not appear to improve strength or exercise capacity; exercise lactate rose in 2 of 3 studies, and oedema and fatigue were more frequent.
Hallazgo de seguridad reportado. GH-treated healthy young adults more often had soft-tissue oedema and fatigue.
- 17Revisión sistemática2007
Systematic review: the safety and efficacy of growth hormone in the healthy elderly.
Liu H, et al. · Ann Intern Med · systematic review/meta-analysis of 18 RCT populations, n=220 GH-treated healthy older adults (mean age 69)
GH reduced fat mass by 2.1 kg and increased lean mass by 2.1 kg without changing weight or bone density, and was associated with more soft-tissue oedema, arthralgias, carpal tunnel syndrome and gynaecomastia, and somewhat more diabetes and impaired fasting glucose.
Hallazgo de seguridad reportado. Healthy older adults given GH had more oedema, arthralgias, carpal tunnel syndrome and gynaecomastia, and somewhat more new-onset diabetes.
- 18Clínico humano2026
Accumulated safety data of recombinant human growth hormone therapy in Korean children over a 10-year period: interim results from the LG Growth Study
Kim YM, et al. · Endocrine Connections · prospective multicentre observational registry, n=5,040 children, 19,878 patient-years (2011-2022)
Adverse drug reactions were reported in 7.0% of registry participants and serious adverse drug reactions in 0.3%, with a malignancy standardised incidence ratio of 1.1 relative to national expectation.
- 19Clínico humano2021
Long-Term Safety of Growth Hormone Treatment in Childhood: Two Large Observational Studies: NordiNet IOS and ANSWER.
Sävendahl L, et al. · J Clin Endocrinol Metab · two multicentre longitudinal observational studies (NordiNet IOS, Europe 2006-2016; ANSWER Program, USA 2002-2016), n=37 702 children, 130 476 patient-years
No indication of increased mortality risk or dose-related increase in adverse events was seen in any risk group. Adverse drug reaction and serious adverse event rates were inversely related to growth hormone dose in the low-risk group.
- 20Clínico humano2020
Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study.
Sävendahl L, et al. · Lancet Diabetes Endocrinol · population cohort (SAGhE), n=24,232 patients treated in childhood, >400,000 patient-years, 8 European countries
All-cause mortality was not increased in low-risk patients with isolated GHD or idiopathic short stature (SMR 1.1), was related to underlying diagnosis in higher-risk groups, and was not associated with GH dose; circulatory and haematological cause-specific mortality was raised in all risk groups.
Hallazgo de seguridad reportado. Cause-specific mortality from circulatory and haematological diseases was increased in all risk groups.
- 21Clínico humano2019
Human growth hormone for poor responders: a randomized placebo-controlled trial provides no evidence for improved live birth rate.
Norman RJ, et al. · Reprod Biomed Online · multicentre randomised double-blind placebo-controlled trial, women with previous poor ovarian response undergoing one IVF cycle (62 growth hormone, 51 placebo), stopped after 4 years before planned numbers were reached
Live birth rate was 14.5% with growth hormone and 13.7% with placebo (odds ratio 1.07), and growth hormone increased the odds of oocyte retrieval but not of embryo transfer. Planned participant numbers were not reached.
- 22Clínico humano2017
Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study.
Swerdlow AJ, et al. · J Clin Endocrinol Metab · population cohort (SAGhE), n=23,984 patients treated with r-hGH, 8 European countries
Raised cancer risks were largely due to second primary cancers in patients treated after a previous cancer; in patients without previous cancer only bone and bladder cancer incidence was significantly raised, and Hodgkin lymphoma incidence increased with longer follow-up.
Hallazgo de seguridad reportado. Bone and bladder cancer incidence was raised in GH-treated patients without prior cancer, and cancer mortality rose with daily dose in those with prior cancer.
- 23Clínico humano2011
Growth hormone plus childhood low-dose estrogen in Turner's syndrome.
Ross JL, et al. · N Engl J Med · randomised double-blind placebo-controlled four-group trial of growth hormone and childhood low-dose estrogen, n=149 girls with Turner syndrome aged 5.0 to 12.5 years, treated to adult height (mean study period 7.2 years)
Growth hormone increased adult height by 0.78 standard-deviation score (5.0 cm) compared with placebo. Adult height was 2.1 cm greater with growth hormone plus childhood low-dose ethinyl estradiol than with growth hormone alone, a difference that did not reach statistical significance (P=0.059).
- 24Clínico humano2010
The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial.
Meinhardt U, et al. · Ann Intern Med · randomised placebo-controlled blinded trial, n=96 recreationally trained athletes (63 men, 33 women), 8 weeks of treatment then a 6-week washout
Growth hormone reduced fat mass and increased lean body mass through an increase in extracellular water, and increased sprint capacity by 3.9% in men and women combined (8.3% in men when combined with testosterone), while endurance, strength and power did not change significantly. The sprint gain was not maintained 6 weeks after stopping, and the authors stated the study was too small to draw conclusions about safety.
- 25Clínico humano2009
Randomized controlled trial to determine the efficacy of long-term growth hormone treatment in severely burned children.
Branski LK, et al. · Ann Surg · single-centre randomised placebo-controlled trial, n=205 children with burns over 40% of total body surface area, follow-up to 24 months after burn
Long-term rhGH improved growth and lean body mass, reduced percent body fat and attenuated hypermetabolism compared with placebo, and improved scarring at 12 months at the two higher doses. Bone mineral content decreased unexpectedly at the highest dose, and cardiac output was lower at 12 and 18 months after burn in the rhGH group.
Hallazgo de seguridad reportado. Bone mineral content fell at the highest dose and cardiac output was reduced at 12 and 18 months after burn with rhGH.
- 26Clínico humano2008
Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
Festen DA, et al. · Clin Endocrinol (Oxf) · randomised controlled trial of growth hormone versus no treatment, n=91 prepubertal children with Prader-Willi syndrome (42 infants, 49 children aged 3-14 years), 1 to 2 years
Over 2 years of growth hormone, median height standard-deviation score rose from -2.3 to -0.4 in infants and from -2.0 to -0.6 in prepubertal children, while it did not increase in untreated children; head circumference normalised, and body fat percentage, lean body mass and body proportions improved without fully normalising. Serum IGF-I rose above the normal range in most treated children.
- 27Clínico humano2004
Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial.
Leschek EW, et al. · J Clin Endocrinol Metab · randomised double-blind placebo-controlled trial, n=68 peripubertal children aged 9-16 years with idiopathic short stature, treated to near adult height (mean 4.4 years)
Adult height, available for 33 participants, was 0.51 standard-deviation score (3.7 cm) greater with growth hormone than with placebo. A modified intention-to-treat analysis of 62 participants showed a similar effect on last observed height (3.8 cm).
- 28Clínico humano2004
Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial.
Hoffman AR, et al. · J Clin Endocrinol Metab · multicentre randomised double-blind placebo-controlled trial, n=166 adults with adult-onset growth hormone deficiency, 12 months
Growth hormone reduced total body and trunk fat and increased lean body mass in men and women, and improved total and LDL cholesterol. No significant treatment effects were seen on strength, endurance, quality of life or bone mineral density.
- 29Clínico humano2003
Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study.
Carel JC, et al. · J Clin Endocrinol Metab · randomised controlled trial of growth hormone versus no treatment, n=168 short adolescents born small for gestational age, treated until adult height (mean 2.7 years)
In the per-protocol analysis (91 treated and 33 controls followed to adult height), adult height was -2.1 standard-deviation score with growth hormone versus -2.7 without treatment, a difference of 0.6. Treatment tolerance was reported as excellent.
- 30Clínico humano2002
Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial.
Blackman MR, et al. · JAMA · randomised double-blind placebo-controlled 2 x 2 factorial trial of growth hormone with or without sex steroids, n=57 women and 74 men aged 65 to 88 years, 26 weeks
Growth hormone, alone or with sex steroids, increased lean body mass and reduced fat mass in both sexes, but strength did not increase significantly except for a marginal gain with growth hormone plus testosterone in men. Adverse effects were frequent: oedema in women given growth hormone (39% vs 0%), arthralgias in men given growth hormone (41% vs 0%), carpal tunnel symptoms with growth hormone plus testosterone (32% vs 0%), and diabetes or glucose intolerance in 18 growth hormone-treated men versus 7 men not given growth hormone.
Hallazgo de seguridad reportado. Diabetes or glucose intolerance developed in 18 growth hormone-treated men versus 7 not receiving growth hormone, with oedema, arthralgias and carpal tunnel symptoms also more common.
- 31Clínico humano2002
Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study.
Sklar CA, et al. · J Clin Endocrinol Metab · cohort analysis within the Childhood Cancer Survivor Study, 361 GH-treated survivors among 13,539 five-year survivors of childhood cancer; the abstract does not say whether the growth hormone was recombinant or pituitary-derived
Growth hormone use was not associated with increased disease recurrence (relative risk 0.83) or death. GH-treated survivors developed 15 second neoplasms, all solid tumours (relative risk 3.21), mainly from a small excess among survivors of acute leukaemia, and the authors cautioned that event numbers were small.
Hallazgo de seguridad reportado. Second neoplasms were increased in GH-treated childhood cancer survivors (relative risk 3.21), mainly among survivors of acute leukaemia.
- 32Clínico humano2000
A preliminary study of growth hormone therapy for Crohn's disease.
Slonim AE, et al. · N Engl J Med · randomised placebo-controlled trial, n=37 adults with moderate-to-severe active Crohn's disease, 4 months, with all patients told to increase protein intake
The Crohn's Disease Activity Index fell by a mean 143 points with growth hormone versus 19 points with placebo, although baseline scores were somewhat higher in the growth hormone group. Oedema (10 patients) and headache (5 patients) occurred with growth hormone and usually resolved within the first month; the authors described the study as preliminary.
- 33Clínico humano2000
Use of human GH in elderly patients with accidental hip fracture.
Van der Lely AJ, et al. · Eur J Endocrinol · multicentre randomised double-blind placebo-controlled trial, n=111 patients older than 60 years with accidental hip fracture, 6 weeks of treatment and 18 further weeks of follow-up
Overall changes in the Barthel Index score showed only non-significant trends. In patients older than 75 years, more returned to their pre-fracture living situation with growth hormone than with placebo (93.8% vs 75.0%), and no safety issues were recorded.
- 34Clínico humano2000
Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment.
Cutfield WS, et al. · Lancet · retrospective analysis of an international pharmacoepidemiological survey, n=23333 children and adolescents treated with growth hormone
Confirmed glucose disorders were found in 43 children (11 type 1 diabetes, 18 type 2 diabetes, 14 impaired glucose tolerance), and type 1 diabetes incidence did not differ from expected values. Type 2 diabetes occurred at 34.4 cases per 100000 years of growth hormone treatment, six-fold higher than reported in children not treated with growth hormone, and did not resolve after treatment stopped.
Hallazgo de seguridad reportado. Type 2 diabetes incidence was six-fold higher than reported in untreated children and did not resolve after growth hormone was stopped.
- 35Clínico humano1999
Increased mortality associated with growth hormone treatment in critically ill adults.
Takala J, et al. · N Engl J Med · two parallel multicentre double-blind randomised placebo-controlled trials, n=247 (Finland) and n=285 (other European countries) critically ill adults after 5 to 7 days in intensive care, treated until intensive-care discharge or for a maximum of 21 days
In-hospital mortality was higher with high-dose growth hormone than with placebo in both trials (39% vs 20% in the Finnish study and 44% vs 18% in the multinational study; relative risk of death 1.9 and 2.4). Among survivors, intensive-care stay, hospital stay and duration of mechanical ventilation were longer in the growth hormone group.
Hallazgo de seguridad reportado. Growth hormone was associated with increased in-hospital mortality in both trials (relative risk of death 1.9 and 2.4).
- 36Clínico humano1998
Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.
Osterziel KJ, et al. · Lancet · randomised double-blind placebo-controlled trial, n=50 patients with chronic heart failure due to dilated cardiomyopathy, at least 12 weeks
Subcutaneous rhGH increased left-ventricular mass by 27% relative to placebo, but left-ventricular systolic wall stress, New York Heart Association class, ejection fraction and 6 min walking distance did not change. One patient given rhGH was withdrawn at 6 weeks because of worsening heart failure.
Hallazgo de seguridad reportado. One rhGH-treated patient was withdrawn at 6 weeks because of worsening heart failure.
- 37Clínico humano1996
Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group.
Schambelan M, et al. · Ann Intern Med · randomised double-blind placebo-controlled multicentre trial (Serostim Study Group), n=178 HIV-infected adults with wasting, 12 weeks
Recombinant human growth hormone increased weight by a mean 1.6 kg and lean body mass by 3.0 kg and reduced body fat by 1.7 kg, while these did not change significantly with placebo, and treadmill work output rose more with growth hormone. Quality-of-life scores, days of disability and medical resource use did not differ, and no significant differences were seen in clinical events, AIDS progression, CD4+ or CD8+ counts or viral burden.
- 38Clínico humano1996
Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience.
Blethen SL, et al. · J Clin Endocrinol Metab · post-marketing surveillance cohort (National Cooperative Growth Study), more than 19,000 children with over 47,000 patient-years of rhGH treatment since 1985
Intracranial hypertension was more common in children treated for renal disease than in those with growth hormone deficiency, and slipped capital femoral epiphysis was less common in idiopathic short stature than in growth hormone deficiency or Turner syndrome. There was no evidence of increased recurrence of leukaemia or central nervous system tumours; 3 new leukaemia cases occurred in children without known risk factors, and growth-attenuating anti-GH antibodies were found in 2 of 5039 children tested.
Hallazgo de seguridad reportado. Intracranial hypertension, slipped capital femoral epiphysis and new leukaemia cases were recorded during rhGH treatment, with intracranial hypertension more frequent in children with renal disease.
- 39Clínico humano1994
Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. Genentech Cooperative Study Group.
Fine RN, et al. · J Pediatr · multicentre randomised double-blind placebo-controlled trial, prepubertal growth-retarded children with chronic renal failure (82 rhGH, 43 placebo), 2 years
Standardised height increased from -2.94 to -1.55 with rhGH and fell from -2.82 to -2.91 with placebo, and growth rates were higher with rhGH in both years without undue bone-age advancement. The change in creatinine clearance did not differ from placebo, and fasting and postprandial insulin were raised at 12 but not at 24 months.
- 40Clínico humano1990
Effects of human growth hormone in men over 60 years old.
Rudman D, et al. · N Engl J Med · controlled trial (treated vs untreated group), n=21 healthy men aged 61 to 81 years with low plasma IGF-I, 6-month baseline then 6-month treatment period (12 treated, 9 untreated)
Six months of biosynthetic human growth hormone raised IGF-I into the youthful range and was accompanied by an 8.8% increase in lean body mass, a 14.4% decrease in adipose-tissue mass and a 1.6% increase in lumbar vertebral bone density, with no significant change at the radius or proximal femur. The untreated group showed no significant changes.
- 41Clínico humano1989
The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency
Salomon F, et al. · The New England Journal of Medicine · double-blind placebo-controlled trial, n=24 adults with growth hormone deficiency, 6 months
Recombinant human growth hormone replacement increased lean body mass by approximately 5.5 kg and decreased fat mass by approximately 5.7 kg over six months, establishing adult growth hormone deficiency as a treatable body-composition phenotype.
- 42Revisión2018
Growth hormone - past, present and future
Ranke MB, Wit JM · Nature Reviews Endocrinology · narrative review covering the history, physiology and therapeutic development of growth hormone
The review traced the transition from cadaveric pituitary-derived growth hormone to recombinant 191-amino-acid somatropin, the expansion of approved indications beyond classical deficiency, and the recurring safety questions attached to that expansion.
Lo que esta evidencia no establece.
Head-to-head long-term data comparing weekly long-acting analogues with daily somatropin remain short in duration, so adult height, sustained metabolic effects and real-world adherence outcomes are not yet established, and the BMI increase observed with long-acting formulations in the first treatment year is of uncertain durability and clinical meaning. Diagnostic criteria for growth hormone deficiency, particularly stimulation-test thresholds in children and at the paediatric-to-adult transition, remain contested, and observational mortality and malignancy surveillance is constrained by selection bias and limited follow-up duration.
Preguntas comunes sobre la investigación.
- What is Somatropin?
Somatropin is recombinant human growth hormone — a 191-amino-acid polypeptide identical in sequence to the hormone produced by the anterior pituitary, manufactured in engineered host cells. It acts directly at the growth hormone receptor.
- How does it differ from Ipamorelin or CJC-1295?
Somatropin is the hormone itself. Ipamorelin and CJC-1295 are secretagogues that prompt the pituitary to release its own growth hormone, which means their effect depends on pituitary reserve and remains subject to endogenous feedback. Somatropin bypasses that step entirely.
- What does long-term safety surveillance of somatropin show?
A prospective multicentre observational registry covering 5,040 children and 19,878 patient-years between 2011 and 2022 recorded adverse drug reactions in 7.0 percent of participants and serious adverse drug reactions in 0.3 percent, with a malignancy standardised incidence ratio of 1.1 relative to national expectation. A 2022 international consensus statement representing ten professional societies concluded that the evidence reviewed did not support an association between growth hormone replacement and primary tumour recurrence or cancer recurrence in survivors, while recommending continued surveillance. Observational mortality and malignancy surveillance remains constrained by selection bias and limited follow-up duration.
Disponible en nuestro catálogo
Solo para fines de investigación. No apto para consumo humano, diagnóstico, tratamiento o prevención de ninguna condición. Nada en esta página constituye consejo médico, y ningún estudio resumido aquí debe leerse como una recomendación.